muramatsu shinichi

FacultyCenterforCommunityMedicineDivisonofOrientalMedicine
Job titleProfessorWeb site

Profile

Profile

Developing gene therapy for neurological diseases

Career

  • 2014
    -
    Today
    The Institute of Medical Science, The University of Tokyo Center for Gene & Cell Therapy, Project Professor
  • 1995
    -
    1997
    米国NIH NHLBI, visiting associate
  • 2007
    -
    Today
    Neurology, Jichi Medical University, Professor

Research Activities

Papers(paper)

  • Neurotransmitter release: vacuolar ATPase V0 sector c-subunits in possible gene or cell therapies for Parkinson's, Alzheimer's, and psychiatric diseases.
    Higashida H, Yokoyama S, Tsuji C, Muramatsu SI
    The journal of physiological sciences : JPS 67(1) 11-17 Jun. 2016
  • Overexpression of Shati/Nat8l, an N-acetyltransferase, in the nucleus accumbens attenuates the response to methamphetamine via activation of group II mGluRs in mice.
    Miyamoto Y, Ishikawa Y, Iegaki N, Sumi K, Fu K, Sato K, Furukawa-Hibi Y, Muramatsu SI, Nabeshima T, Uno K, Nitta A
    The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 17(8) 1-12 Feb. 2014
  • Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys.
    Kanazawa M, Ohba H, Harada N, Kakiuchi T, Muramatsu S, Tsukada H
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine 57(2) 303-308 Feb. 2016
  • Intrastriatal gene delivery of GDNF persistently attenuates methamphetamine self-administration and relapse in mice.
    Yan Y, Miyamoto Y, Nitta A, Muramatsu S, Ozawa K, Yamada K, Nabeshima T
    The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 16(7) 1559-1567 Aug. 2013
  • Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9-ADAR2 delivery to motor neurons.
    Yamashita T, Chai HL, Teramoto S, Tsuji S, Shimazaki K, Muramatsu S, Kwak S
    EMBO molecular medicine 5(11) 1710-1719 Nov. 2013
  • A Novel Reporter Rat Strain That Conditionally Expresses the Bright Red Fluorescent Protein tdTomato.
    Igarashi H, Koizumi K, Kaneko R, Ikeda K, Egawa R, Yanagawa Y, Muramatsu S, Onimaru H, Ishizuka T, Yawo H
    PloS one 11(5) e0155687 2016
  • Regulation of the dopaminergic system in a murine model of aromatic L-amino acid decarboxylase deficiency.
    Lee NC, Shieh YD, Chien YH, Tzen KY, Yu IS, Chen PW, Hu MH, Hu MK, Muramatsu S, Ichinose H, Hwu WL
    Neurobiology of disease 52 177-190 Apr. 2013
  • Freezing of Gait in Parkinson’s Disease Is Associated with Reduced 6-[18F]Fluoro-L-m-tyrosine Uptake in the Locus Coeruleus
    Ono SA, Sato T, Muramatsu S
    Parkinson's disease 2016 5430920 2016
  • Induction of neuronal axon outgrowth by Shati/Nat8l by energy metabolism in mice cultured neurons.
    Sumi K, Uno K, Matsumura S, Miyamoto Y, Furukawa-Hibi Y, Muramatsu S, Nabeshima T, Nitta A
    Neuroreport 26(13) 740-746 Sep. 2015
  • [IT network establishment for neuropatients].
    Abe K, Uchiyama S, Matsubara E, Muramatsu S, Atsuta N, Kitagawa K, Iguchi Y, Ooboshi H, Kaji R, Terao Y
    Rinsho shinkeigaku = Clinical neurology 53(11) 1155-1158 2013
Display all
Papers(paper)close
  • Neurotransmitter release: vacuolar ATPase V0 sector c-subunits in possible gene or cell therapies for Parkinson's, Alzheimer's, and psychiatric diseases.
    Higashida H, Yokoyama S, Tsuji C, Muramatsu SI
    The journal of physiological sciences : JPS 67(1) 11-17 Jun. 2016
  • Overexpression of Shati/Nat8l, an N-acetyltransferase, in the nucleus accumbens attenuates the response to methamphetamine via activation of group II mGluRs in mice.
    Miyamoto Y, Ishikawa Y, Iegaki N, Sumi K, Fu K, Sato K, Furukawa-Hibi Y, Muramatsu SI, Nabeshima T, Uno K, Nitta A
    The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 17(8) 1-12 Feb. 2014
  • Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys.
    Kanazawa M, Ohba H, Harada N, Kakiuchi T, Muramatsu S, Tsukada H
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine 57(2) 303-308 Feb. 2016
  • Intrastriatal gene delivery of GDNF persistently attenuates methamphetamine self-administration and relapse in mice.
    Yan Y, Miyamoto Y, Nitta A, Muramatsu S, Ozawa K, Yamada K, Nabeshima T
    The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 16(7) 1559-1567 Aug. 2013
  • Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9-ADAR2 delivery to motor neurons.
    Yamashita T, Chai HL, Teramoto S, Tsuji S, Shimazaki K, Muramatsu S, Kwak S
    EMBO molecular medicine 5(11) 1710-1719 Nov. 2013
  • A Novel Reporter Rat Strain That Conditionally Expresses the Bright Red Fluorescent Protein tdTomato.
    Igarashi H, Koizumi K, Kaneko R, Ikeda K, Egawa R, Yanagawa Y, Muramatsu S, Onimaru H, Ishizuka T, Yawo H
    PloS one 11(5) e0155687 2016
  • Regulation of the dopaminergic system in a murine model of aromatic L-amino acid decarboxylase deficiency.
    Lee NC, Shieh YD, Chien YH, Tzen KY, Yu IS, Chen PW, Hu MH, Hu MK, Muramatsu S, Ichinose H, Hwu WL
    Neurobiology of disease 52 177-190 Apr. 2013
  • Freezing of Gait in Parkinson’s Disease Is Associated with Reduced 6-[18F]Fluoro-L-m-tyrosine Uptake in the Locus Coeruleus
    Ono SA, Sato T, Muramatsu S
    Parkinson's disease 2016 5430920 2016
  • Induction of neuronal axon outgrowth by Shati/Nat8l by energy metabolism in mice cultured neurons.
    Sumi K, Uno K, Matsumura S, Miyamoto Y, Furukawa-Hibi Y, Muramatsu S, Nabeshima T, Nitta A
    Neuroreport 26(13) 740-746 Sep. 2015
  • [IT network establishment for neuropatients].
    Abe K, Uchiyama S, Matsubara E, Muramatsu S, Atsuta N, Kitagawa K, Iguchi Y, Ooboshi H, Kaji R, Terao Y
    Rinsho shinkeigaku = Clinical neurology 53(11) 1155-1158 2013
  • Na, K-ATPase α3 is a death target of Alzheimer patient amyloid-β assembly.
    Ohnishi T, Yanazawa M, Sasahara T, Kitamura Y, Hiroaki H, Fukazawa Y, Kii I, Nishiyama T, Kakita A, Takeda H, Takeuchi A, Arai Y, Ito A, Komura H, Hirao H, Satomura K, Inoue M, Muramatsu S, Matsui K, Tada M, Sato M, Saijo E, Shigemitsu Y, Sakai S, Umetsu Y, Goda N, Takino N, Takahashi H, Hagiwara M, Sawasaki T, Iwasaki G, Nakamura Y, Nabeshima Y, Teplow DB, Hoshi M
    Proceedings of the National Academy of Sciences of the United States of America 112(32) E4465-74 Aug. 2015
  • Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice.
    Iwata N, Sekiguchi M, Hattori Y, Takahashi A, Asai M, Ji B, Higuchi M, Staufenbiel M, Muramatsu S, Saido TC
    Scientific reports 3 1472 2013
  • [Basic knowledge about Kampo for neurologists].
    Muramatsu S
    Rinsho shinkeigaku = Clinical neurology 53(11) 934-937 2013
  • Anterograde C1ql1 signaling is required in order to determine and maintain a single-winner climbing fiber in the mouse cerebellum.
    Kakegawa W, Mitakidis N, Miura E, Abe M, Matsuda K, Takeo YH, Kohda K, Motohashi J, Takahashi A, Nagao S, Muramatsu S, Watanabe M, Sakimura K, Aricescu AR, Yuzaki M
    Neuron 85(2) 316-329 Jan. 2015
  • Systemic delivery of tyrosine-mutant AAV vectors results in robust transduction of neurons in adult mice.
    Iida A, Takino N, Miyauchi H, Shimazaki K, Muramatsu S
    BioMed research international 2013 974819 2013
  • HMGB1 facilitates repair of mitochondrial DNA damage and extends the lifespan of mutant ataxin-1 knock-in mice.
    Ito H, Fujita K, Tagawa K, Chen X, Homma H, Sasabe T, Shimizu J, Shimizu S, Tamura T, Muramatsu S, Okazawa H
    EMBO molecular medicine 7(1) 78-101 Dec. 2014
  • AADC deficiency: occurring in humans, modeled in rodents.
    Hwu WL, Lee NC, Chien YH, Muramatsu S, Ichinose H
    Advances in pharmacology (San Diego, Calif.) 68 273-284 2013
  • [The role of a molecule associated with drug dependence, shati/nat8l].
    Miyamoto Y, Saika E, Hori E, Iegaki N, Sumi K, Nabeshima T, Muramatsu S, Nishijo H, Uno K, Nitta A
    Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology 33(4) 167-173 Aug. 2013
  • Current status of Kampo medicine curricula in all Japanese medical schools.
    Arai M, Katai S, Muramatsu S, Namiki T, Hanawa T, Izumi S
    BMC complementary and alternative medicine 12 207 Nov. 2012
  • Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2.
    Miyazaki Y, Adachi H, Katsuno M, Minamiyama M, Jiang YM, Huang Z, Doi H, Matsumoto S, Kondo N, Iida M, Tohnai G, Tanaka F, Muramatsu SI, Sobue G
    Nature medicine 18(7) 1136-1141 Jun. 2012
  • Careful clinical observation is essential for diagnosis of Huntington's disease.
    Nakamura K, Ota M, Kawata A, Isozaki E, Muramatsu S, Matsubara S
    Arquivos de neuro-psiquiatria 70 646 Aug. 2012
  • Gene therapy for aromatic L-amino acid decarboxylase deficiency.
    Hwu WL, Muramatsu S, Tseng SH, Tzen KY, Lee NC, Chien YH, Snyder RO, Byrne BJ, Tai CH, Wu RM
    Science translational medicine 4(134) 134ra61 May 2012
  • Dopamine release via the vacuolar ATPase V0 sector c-subunit, confirmed in N18 neuroblastoma cells, results in behavioral recovery in hemiparkinsonian mice.
    Jin D, Muramatsu SI, Shimizu N, Yokoyama S, Hirai H, Yamada K, Liu HX, Higashida C, Hashii M, Higashida A, Asano M, Ohkuma S, Higashida H
    Neurochemistry international 61(6) 907-912 Jan. 2012
  • Careful clinical observation is essential for diagnosis of Huntington's disease | Observação clínica cuidadosa é essencial para o diagnóstico da doença de Huntington
    Nakamura K, Ota M, Kawata A, Isozaki E, Muramatsu S, Matsubara S.
    Arquivos de Neuro-Psiquiatria 70(8) 645-649 2012
  • Compensatory regulation of dopamine after ablation of the tyrosine hydroxylase gene in the nigrostriatal projection.
    Tokuoka H, Muramatsu S, Sumi-Ichinose C, Sakane H, Kojima M, Aso Y, Nomura T, Metzger D, Ichinose H
    The Journal of biological chemistry 286(50) 43549-43558 Dec. 2011
  • Gene therapy for Parkinson's disease
    Muramatsu S.-I.
    Clinical Neurology 52(11) 896-898 2012
  • Subregional 6-[18F]fluoro-ʟ-m-tyrosine uptake in the striatum in Parkinson's disease.
    Asari S, Fujimoto K, Miyauchi A, Sato T, Nakano I, Muramatsu S
    BMC neurology 11 35 Mar. 2011
  • Hsp40 gene therapy exerts therapeutic effects on polyglutamine disease mice via a non-cell autonomous mechanism.
    Popiel HA, Takeuchi T, Fujita H, Yamamoto K, Ito C, Yamane H, Muramatsu S, Toda T, Wada K, Nagai Y
    PloS one 7(11) e51069 2012
  • A pregnant woman with clinical and radiological findings compatible with posterior reversible encephalopathy syndrome in early pregnancy without discernable underlying disorders: Atypical type of this syndrom
    Matsubara S, Fujita A, Muramatsu S.-I, Usui R, Chikazawa K, Suzuki M.
    Journal of Obstetrics and Gynaecology Research 37(8) 1137-1140 2011
  • Rhabdomyolysis caused by tocolytic therapy with oral ritodrine hydrochloride in a pregnant woman with placenta previa: Is this a rare case with a latent predisposing condition?
    Matsubara S, Muramatsu S.-I.
    Journal of Obstetrics and Gynaecology Research 37(6) 2011
  • A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease.
    Muramatsu S, Fujimoto K, Kato S, Mizukami H, Asari S, Ikeguchi K, Kawakami T, Urabe M, Kume A, Sato T, Watanabe E, Ozawa K, Nakano I
    Molecular therapy : the journal of the American Society of Gene Therapy 18(9) 1731-1735 Sep. 2010
  • Retinoid x receptor gamma control of affective behaviors involves dopaminergic signaling in mice.
    Krzyzosiak A, Szyszka-Niagolov M, Wietrzych M, Gobaille S, Muramatsu S, Krezel W
    Neuron 66(6) 908-920 Jun. 2010
  • Gene therapy in Alzheimer's disease -potential for disease modification.
    Nilsson P, Iwata N, Muramatsu SI, Tjernberg LO, Winblad B, Saido TC
    Journal of cellular and molecular medicine Feb. 2010
  • Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons.
    Kadkhodaei B, Ito T, Joodmardi E, Mattsson B, Rouillard C, Carta M, Muramatsu S, Sumi-Ichinose C, Nomura T, Metzger D, Chambon P, Lindqvist E, Larsson NG, Olson L, Björklund A, Ichinose H, Perlmann T
    The Journal of neuroscience : the official journal of the Society for Neuroscience 29 15923-15932 Dec. 2009
  • A convenient enzyme-linked immunosorbent assay for rapid screening of anti-adeno-associated virus neutralizing antibodies.
    Ito T, Yamamoto S, Hayashi T, Kodera M, Mizukami H, Ozawa K, Muramatsu S
    Annals of clinical biochemistry 46(6) 508-510 Nov. 2009
  • [Cell therapy for Parkinson disease]
    Muramatsu S
    Rinsho shinkeigaku = Clinical neurology 49(11) 890-892 Nov. 2009
  • Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains.
    Noguchi A, Matsumura S, Dezawa M, Tada M, Yanazawa M, Ito A, Akioka M, Kikuchi S, Sato M, Ideno S, Noda M, Fukunari A, Muramatsu S, Itokazu Y, Sato K, Takahashi H, Teplow DB, Nabeshima Y, Kakita A, Imahori K, Hoshi M
    The Journal of biological chemistry 284(47) 32895-32905 Nov. 2009
  • The cardiac pacemaker-specific channel Hcn4 is a direct transcriptional target of MEF2.
    Kuratomi S, Ohmori Y, Ito M, Shimazaki K, Muramatsu S, Mizukami H, Uosaki H, Yamashita JK, Arai Y, Kuwahara K, Takano M
    Cardiovascular research 83 682-687 Sep. 2009
  • Multitracer assessment of dopamine function after transplantation of embryonic stem cell-derived neural stem cells in a primate model of Parkinson's disease.
    Muramatsu S, Okuno T, Suzuki Y, Nakayama T, Kakiuchi T, Takino N, Iida A, Ono F, Terao K, Inoue N, Nakano I, Kondo Y, Tsukada H
    Synapse (New York, N.Y.) 63 541-548 Jul. 2009
  • Self-contained induction of neurons from human embryonic stem cells.
    Okuno T, Nakayama T, Konishi N, Michibata H, Wakimoto K, Suzuki Y, Nito S, Inaba T, Nakano I, Muramatsu S, Takano M, Kondo Y, Inoue N
    PloS one 4 e6318 Jul. 2009
  • Ablation of NMDA receptors enhances the excitability of hippocampal CA3 neurons.
    Fukushima F, Nakao K, Shinoe T, Fukaya M, Muramatsu S, Sakimura K, Kataoka H, Mori H, Watanabe M, Manabe T, Mishina M
    PloS one 4 e3993 2009
  • ERas is expressed in primate embryonic stem cells but not related to tumorigenesis.
    Tanaka Y, Ikeda T, Kishi Y, Masuda S, Shibata H, Takeuchi K, Komura M, Iwanaka T, Muramatsu S, Kondo Y, Takahashi K, Yamanaka S, Hanazono Y
    Cell transplantation 18 381-389 2009
  • Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice.
    Wakamatsu M, Ishii A, Iwata S, Sakagami J, Ukai Y, Ono M, Kanbe D, Muramatsu S, Kobayashi K, Iwatsubo T, Yoshimoto M
    Neurobiology of aging 29 574-585 Apr. 2008
  • Protection against aminoglycoside-induced ototoxicity by regulated AAV vector-mediated GDNF gene transfer into the cochlea.
    Liu Y, Okada T, Shimazaki K, Sheykholeslami K, Nomoto T, Muramatsu S, Mizukami H, Kume A, Xiao S, Ichimura K, Ozawa K
    Molecular therapy : the journal of the American Society of Gene Therapy 16 474-480 Mar. 2008
  • Variation in the incidence of teratomas after the transplantation of nonhuman primate ES cells into immunodeficient mice.
    Kishi Y, Tanaka Y, Shibata H, Nakamura S, Takeuchi K, Masuda S, Ikeda T, Muramatsu S, Hanazono Y
    Cell transplantation 17 1095-1102 2008
  • Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Sawada H, Hishida R, Hirata Y, Ono K, Suzuki H, Muramatsu S, Nakano I, Nagatsu T, Sawada M
    Journal of neuroscience research 85 1752-1761 Jun. 2007
  • [Gene therapy for Parkinson's disease]
    Muramatsu S
    Brain and nerve = Shinkei kenkyu no shinpo 59 425-430 Apr. 2007
  • Acupuncture and knee osteoarthritis.
    Muramatsu S
    Annals of internal medicine 146 147; author reply 148-9 Jan. 2007
  • Improved safety of hematopoietic transplantation with monkey embryonic stem cells in the allogeneic setting.
    Shibata H, Ageyama N, Tanaka Y, Kishi Y, Sasaki K, Nakamura S, Muramatsu S, Hayashi S, Kitano Y, Terao K, Hanazono Y
    Stem cells (Dayton, Ohio) 24(6) 1450-1457 Jun. 2006
  • Viral-mediated temporally controlled dopamine production in a rat model of Parkinson disease.
    Li XG, Okada T, Kodera M, Nara Y, Takino N, Muramatsu C, Ikeguchi K, Urano F, Ichinose H, Metzger D, Chambon P, Nakano I, Ozawa K, Muramatsu S
    Molecular therapy : the journal of the American Society of Gene Therapy 13 160-166 Jan. 2006
  • [Gene therapy for Parkinson's disease]
    Muramatsu S
    Nippon rinsho. Japanese journal of clinical medicine 63 Suppl 12 622-625 Dec. 2005
  • [Gene therapy and cell transplantation for Parkinson's disease]
    Muramatsu S
    Rinsho shinkeigaku = Clinical neurology 45 902-904 Nov. 2005
  • Specific and efficient transduction of Cochlear inner hair cells with recombinant adeno-associated virus type 3 vector.
    Liu Y, Okada T, Sheykholeslami K, Shimazaki K, Nomoto T, Muramatsu S, Kanazawa T, Takeuchi K, Ajalli R, Mizukami H, Kume A, Ichimura K, Ozawa K
    Molecular therapy : the journal of the American Society of Gene Therapy 12 725-733 Oct. 2005
  • Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease.
    Maruyama M, Higuchi M, Takaki Y, Matsuba Y, Tanji H, Nemoto M, Tomita N, Matsui T, Iwata N, Mizukami H, Muramatsu S, Ozawa K, Saido TC, Arai H, Sasaki H
    Annals of neurology 57 832-842 Jun. 2005
  • Gene therapy for Parkinson's disease using recombinant adeno-associated viral vectors.
    Muramatsu S, Tsukada H, Nakano I, Ozawa K
    Expert opinion on biological therapy 5 663-671 May 2005
  • Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice.
    Nakai H, Fuess S, Storm TA, Muramatsu S, Nara Y, Kay MA
    Journal of virology 79(1) 214-224 Jan. 2005
  • [ES cell therapy for Parkinson's disease]
    Nara Y, Muramatsu S, Nakano I
    Nippon rinsho. Japanese journal of clinical medicine 62 1643-1647 Sep. 2004
  • Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain.
    Iwata N, Mizukami H, Shirotani K, Takaki Y, Muramatsu S, Lu B, Gerard NP, Gerard C, Ozawa K, Saido TC
    The Journal of neuroscience : the official journal of the Society for Neuroscience 24 991-998 Jan. 2004
  • Efficient gene transfer of a simian immuno-deficiency viral vector into cardiomyocytes derived from primate embryonic stem cells.
    Nagata M, Takahashi M, Muramatsu S, Ueda Y, Hanazono Y, Takeuchi K, Okada K, Suzuki Y, Kondo Y, Suemori M, Ikeda U, Nakano I, Kobayashi E, Hasegawa M, Ozawa K, Nakatsuji N, Shimada K
    The journal of gene medicine 5 921-928 Nov. 2003
  • Intramuscular injection of AAV-GDNF results in sustained expression of transgenic GDNF, and its delivery to spinal motoneurons by retrograde transport.
    Lu YY, Wang LJ, Muramatsu S, Ikeguchi K, Fujimoto K, Okada T, Mizukami H, Matsushita T, Hanazono Y, Kume A, Nagatsu T, Ozawa K, Nakano I
    Neuroscience research 45(1) 33-40 Jan. 2003
  • Adeno-associated viral vectors for Parkinson's disease.
    Muramatsu S, Wang L, Ikeguchi K, Fujimoto K, Nakano I, Okada T, Mizukami H, Hanazono Y, Kume A, Nakano I, Ozawa K
    International review of neurobiology 55 205-222 2003
  • Adeno-associated virus vectors for gene transfer to the brain.
    Okada T, Nomoto T, Shimazaki K, Lijun W, Lu Y, Matsushita T, Mizukami H, Urabe M, Hanazono Y, Kume A, Muramatsu S, Nakano I, Ozawa K
    Methods (San Diego, Calif.) 28 237-247 Oct. 2002
  • Recombinant adeno-associated viral vectors bring gene therapy for Parkinson's disease closer to reality.
    Muramatsu S, Wang L, Ikeguchi K, Fujimoto K, Nakano I, Ozawa K
    Journal of neurology 249 Suppl 2 II36-40 Sep. 2002
  • Highly efficient gene transfer into primate embryonic stem cells with a simian lentivirus vector.
    Asano T, Hanazono Y, Ueda Y, Muramatsu S, Kume A, Suemori H, Suzuki Y, Kondo Y, Harii K, Hasegawa M, Nakatsuji N, Ozawa K
    Molecular therapy : the journal of the American Society of Gene Therapy 6 162-168 Aug. 2002
  • Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis.
    Wang LJ, Lu YY, Muramatsu S, Ikeguchi K, Fujimoto K, Okada T, Mizukami H, Matsushita T, Hanazono Y, Kume A, Nagatsu T, Ozawa K, Nakano I
    The Journal of neuroscience : the official journal of the Society for Neuroscience 22 6920-6928 Aug. 2002
  • [A case of Crow-Fukase syndrome with respiratory failure due to bilateral diaphragmatic paralysis]
    Namekawa M, Muramatsu S, Hashimoto R, Kawakami T, Fujimoto K, Nakano I
    Rinsho shinkeigaku = Clinical neurology 42 635-638 Jul. 2002
  • Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes.
    Muramatsu S, Fujimoto K, Ikeguchi K, Shizuma N, Kawasaki K, Ono F, Shen Y, Wang L, Mizukami H, Kume A, Matsumura M, Nagatsu I, Urano F, Ichinose H, Nagatsu T, Terao K, Nakano I, Ozawa K
    Human gene therapy 13 345-354 Feb. 2002
  • Gene therapy for mitochondrial disease by delivering restriction endonuclease SmaI into mitochondria.
    Tanaka M, Borgeld HJ, Zhang J, Muramatsu S, Gong JS, Yoneda M, Maruyama W, Naoi M, Ibi T, Sahashi K, Shamoto M, Fuku N, Kurata M, Yamada Y, Nishizawa K, Akao Y, Ohishi N, Miyabayashi S, Umemoto H, Muramatsu T, Furukawa K, Kikuchi A, Nakano I, Ozawa K, Yagi K
    Journal of biomedical science 9 534-541 2002
  • Gene therapy for a mouse model of glucose transporter-1 deficiency syndrome.
    Nakamura S, Osaka H, Muramatsu SI, Takino N, Ito M, Aoki S, Jimbo EF, Shimazaki K, Onaka T, Ohtsuki S, Terasaki T, Yamagata T
    Molecular genetics and metabolism reports 10 67-74 Mar. 2017
  • Persistent Expression of Dopamine-Synthesizing Enzymes 15 Years after Gene Transfer in a Primate Model of Parkinson's Disease.
    Sehara Y, Fujimoto KI, Ikeguchi K, Katakai Y, Ono F, Takino N, Ito M, Ozawa K, Muramatsu SI
    Human gene therapy. Clinical development Mar. 2017
  • RpA1 ameliorates symptoms of mutant ataxin-1 knock-in mice and enhances DNA damage repair.
    Taniguchi JB, Kondo K, Fujita K, Chen X, Homma H, Sudo T, Mao Y, Watase K, Tanaka T, Tagawa K, Tamura T, Muramatsu SI, Okazawa H
    Human molecular genetics 25(20) 4432-4447 Oct. 2016
  • An miRNA-mediated therapy for SCA6 blocks IRES-driven translation of the CACNA1A second cistron.
    Miyazaki Y, Du X, Muramatsu S, Gomez CM
    Science translational medicine 8(347) 347ra94 Jul. 2016
  • Benefits of Neuronal Preferential Systemic Gene Therapy for Neurotransmitter Deficiency.
    Lee NC, Muramatsu SI, Chien YH, Liu WS, Wang WH, Cheng CH, Hu MK, Chen PW, Tzen KY, Byrne BJ, Hwu WL
    Molecular therapy : the journal of the American Society of Gene Therapy 23(10) 1572-1581 Oct. 2015

Prize

  • Jul. 2011 Takara Bio Award, Japan Society of Gene Therapy
  • Jun. 2009 Top Abstract, American Society of Gene Therapy
  • Jun. 2000 The 6th JSGT Award, Japan Society of Gene Therapy
Display all
Prizeclose
  • Jul. 2011 Takara Bio Award, Japan Society of Gene Therapy
  • Jun. 2009 Top Abstract, American Society of Gene Therapy
  • Jun. 2000 The 6th JSGT Award, Japan Society of Gene Therapy


Copyright c MEDIA FUSION Co.,Ltd. All rights reserved.